ViroGates A/S (OCSE:VIRO) ROCE % : -72.20% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ViroGates A/S's annualized ROCE % for the quarter that ended in Mar. 2024 was -72.20%.

ViroGates A/S ROCE % Historical Data

The historical data trend for ViroGates A/S's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates A/S ROCE % Chart

ViroGates A/S Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-38.19

-53.57

-78.64

-66.21

-65.22

ViroGates A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-89.21	-111.13	-64.49	-72.91	-72.20

ViroGates A/S ROCE % Calculation

ViroGates A/S's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-12.521	/	( ( (17.539 - 1.451)	+	(24.555 - 2.248) )	/ 2 )
	=	-12.521	/	( (16.088	+	22.307)	/ 2 )
	=	-12.521	/	19.1975
	=	-65.22 %

ViroGates A/S's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-14.808	/	( ( (24.555 - 2.248)	+	(20.177 - 1.466) )	/ 2 )
	=	-14.808	/	( ( 22.307	+	18.711 )	/ 2 )
	=	-14.808	/	20.509
	=	-72.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

ViroGates A/S (OCSE:VIRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ViroGates A/S ROCE % Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ViroGates A/S (OCSE:VIRO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Banevaenget 13, Birkerod, DNK, DK-3460

Website

https://www.virogates.com

ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates A/S (OCSE:VIRO) Headlines

No Headlines